Copyright
©The Author(s) 2021.
World J Gastrointest Oncol. Dec 15, 2021; 13(12): 2088-2100
Published online Dec 15, 2021. doi: 10.4251/wjgo.v13.i12.2088
Published online Dec 15, 2021. doi: 10.4251/wjgo.v13.i12.2088
Table 1 Final patient diagnoses
Benign group (n = 22) | Malignant group (n = 12) | ||
Chronic pancreatitis | 6 | Pancreatic cancer, stage (I/II/III/IV) | 9 (2/5/1/1/) |
IPMN | 5 | Biliary ductal cancer, stage (I/II/III/IV) | 3 (1/2/0/0) |
GB ADM | 3 | ||
Autoimmune pancreatitis | 3 | ||
CBD stricture of unknown origin | 2 | ||
Serous cystic neoplasm | 2 | ||
CBD stone | 1 |
Table 2 Comparison of patient characteristics, tumor markers, and microbiomes
Benign group (n = 22) | Malignant group (n = 12) | P value | |
Age, yr (mean ± SD) | 63.0 ± 12.2 | 73.0 ± 8.3 | 0.016 |
Sex (male/female) | 8/14 | 4/8 | 1.0 |
Reduction in body weight ≥ 5 kg within 6 mo before duodenal juice sampling, n (%) | 1 (4.5) | 2 (16.7) | 0.28 |
Intake of proton pump inhibitors, n (%) | 4 (18.2) | 2 (16.7) | 1.0 |
CA19-9, U/mL, median (range) | 5.4 (2.0-54.8) | 22.8 (2.0-9893.2) | 0.03 |
Table 3 Microbiome comparison
Benign group (n = 22) | Malignant group (n = 12) | P value | |
Bacteroides, %, median (range) | 4.3 (0-26.1) | 5.6 (0-46.4) | 0.55 |
Bifidobacterium, %, median (range) | 0 (0-0.5) | 0.3 (0-4.5) | < 0.05 |
Clostridium cluster IV, %, median (range) | 2.9 (0-10.8) | 3.4 (0-8.8) | 0.80 |
Clostridium cluster IX, %, median (range) | 4.7 (0.6-19.5) | 4.9 (0-17.8) | 0.68 |
Clostridium cluster XI, %, median (range) | 0 (0-0) | 0 (0-0) | |
Clostridium cluster XVIII, %, median (range) | 1.3 (0-3.9) | 3.6 (0.8-14.9) | 0.006 |
Clostridium subcluster XIVa, %, median (range) | 5.1 (0-23.1) | 6.4 (2.9-13.7) | 0.38 |
Lactobacillales, %, mean ± SD | 63.0 ± 19.7 | 62.6 ± 18.3 | 0.95 |
Prevotella, %, median (range) | 2.2 (0-25.9) | 0.1 (0-10.9) | 0.04 |
Others, %, median (range) | 4.9 (2.5-20.4) | 4.1 (1.5-6.3) | 0.14 |
Table 4 Effects of age on cancer antigen 19-9 levels and the human microbiome
Age < 69 yr (n = 17) | Age ≥ 69 yr (n = 17) | P value | |
CA19-9, U/mL, median (range) | 7.1 (2-129.3) | 4.9 (2-9893.2) | 0.77 |
Bifidobacterium, %, median (range) | 0.3 (0-0.5) | 0 (0-4.5) | 0.3 |
Clostridium cluster XVIII, %, median (range) | 2.6 (0-5.7) | 1.8 (0-14.9) | 0.82 |
Prevotella, %, median (range) | 1.3 (0-18.2) | 1.9 (0-25.9) | 0.56 |
Table 5 Diagnosis of pancreaticobiliary cancer by the combination of Clostridium cluster XVIII and cancer antigen 19-9 levels
Table 6 Past reports on microbes and pancreaticobiliary cancer
Disease | Ref. | Microbes | Sample | Role |
Pancreatic cancer | Michaud et al[30] | A history of periodontal diseases | Risk factor | |
Farrell et al[28] | A combination of Neisseria elongate and Streptococcus mitis | Oral | Distinguishing from healthy controls | |
Torres et al[29] | Ratio of Leptotrichia to Porphyromonas | Saliva | Higher in pancreatic cancer patients | |
Fan et al[27] | Porphyromonas gingivalis | Oral, antibody | Risk factor | |
Olson et al[39] | Firmicutes | Oral | More abundant | |
Lu et al[40] | Leptotrichia, Fusobacterium, Rothia, Actinomyces, Corynebacterium, Atopobium, Peptostreptococcus, Catonella, Oribacterium, Filifactor, Campylobacter, Moraxella, Tannerella | Tongue coating | More prevalent | |
Mei et al[46] | Acinetobactor, Aquabacterium, Oceanobacillus, Rahnella, Massilia, Delftia, Deinococcus, Sphingobium | Duodenal mucosa | More abundant | |
Mitsuhashi et al[43] | Fusobacterium species | Cancer tissue | Poor prognosis | |
Riquelme et al[44] | Pseudoxanthomonas, Streptomyces, Saccharopolyspora, Bacillus clausii | Cancer tissue | Long-term survival | |
Pancreatic and ampullary cancer | Di Calro et al[45] | Escherichia coli, Klebsiella pneumoniae | Bile juice | Predictor for survival |
IPMN with high-grade dysplasia | Gaiser et al[47] | Granulicatella adiacens, Fusobacterium nucleatum | Cyst fluid | More abundant |
Table 7 Microbiome comparison in patients with pancreatic disease
Benign pancreatic diseases (n = 16) | Pancreatic cancer (n = 9) | P value | |
Bacteroides, %, median (range) | 2.1 (0-26.1) | 5.8 (0-46.4) | 0.17 |
Bifidobacterium, %, median (range) | 0 (0-0.5) | 0.48 (0-4.5) | 0.03 |
Clostridium cluster IV, %, mean ± SD | 4.0 ± 3.3 | 3.6 ± 2.9 | 0.76 |
Clostridium cluster IX, %, mean ± SD | 5.3 ± 3.6 | 6.4 ± 5.2 | 0.57 |
Clostridium cluster XI, %, median (range) | 0 (0-0) | 0 (0-0) | |
Clostridium cluster XVIII, %, median (range) | 1.4 (0-3.9) | 3.0 (0.8-14.9) | 0.04 |
Clostridium subcluster XIVa, %, median (range) | 3.8 (0-21.4) | 6.0 (2.9-13.7) | 0.32 |
Lactobacillales, %, mean ± SD | 68.4 ± 19.3 | 59.7 ± 20.4 | 0.3 |
Prevotella, %, median (range) | 4.2 (2.5-20.4) | 4.0 (1.5-6.3) | 0.3 |
Others, %, median (range) | 2.0 (0-18.3) | 0.3 (0-11.0) | 0.3 |
- Citation: Sugimoto M, Abe K, Takagi T, Suzuki R, Konno N, Asama H, Sato Y, Irie H, Watanabe K, Nakamura J, Kikuchi H, Takasumi M, Hashimoto M, Kato T, Kobashi R, Hikichi T, Ohira H. Dysbiosis of the duodenal microbiota as a diagnostic marker for pancreaticobiliary cancer. World J Gastrointest Oncol 2021; 13(12): 2088-2100
- URL: https://www.wjgnet.com/1948-5204/full/v13/i12/2088.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v13.i12.2088